Skip to main content
ChemPartner PharmaTech Co., Ltd. logo

ChemPartner PharmaTech Co., Ltd. — Investor Relations & Filings

Ticker · 300149 ISIN · CNE100000Y27 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,256 across all filing types
Latest filing 2017-04-14 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300149

About ChemPartner PharmaTech Co., Ltd.

https://www.chempartner.com

ChemPartner PharmaTech Co., Ltd. is a global research and development organization providing comprehensive drug discovery and development services. Operating as a Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO), the company supports pharmaceutical and biotechnology clients through an integrated service platform. Core capabilities include medicinal chemistry, biology, pharmacology, drug metabolism and pharmacokinetics (DMPK), and toxicology. The organization also offers specialized expertise in biologics discovery, protein engineering, and antibody development. ChemPartner facilitates the transition from early-stage research to clinical development through its pharmaceutical development and manufacturing capabilities, utilizing advanced technology to accelerate the discovery and production of novel therapeutic agents.

Recent filings

Filing Released Lang Actions
独立董事关于公司使用部分超募资金投资设立微生态医疗公司暨关联交易的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent opinion from the independent directors of a company regarding the use of part of the company's over-raised funds to invest in establishing a micro-ecological medical company, which is a related party transaction. It references compliance with Shenzhen Stock Exchange rules and internal company regulations. The document is short (818 characters) and consists mainly of an opinion and signatures from independent directors. It does not contain financial statements, audit results, or detailed financial data. It is not an announcement of voting results, nor a full report like an Annual Report or Interim Report. It is a regulatory compliance-related opinion document related to a specific transaction and fund usage. Such documents typically fall under Regulatory Filings (RNS) as they do not fit other specific categories and are compliance-related disclosures.
2017-04-14 Chinese
广发证券股份有限公司关于公司重组停牌期间重组进展信息披露真实性、继续停牌合理性和六个月内复牌可行性的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed independent financial advisor's verification opinion regarding the authenticity of information disclosure during a major asset restructuring suspension period, the reasonableness of continued suspension, and the feasibility of resuming trading within six months. It references regulatory requirements and multiple announcements related to the suspension and resumption of trading due to a major asset restructuring. The document is not a full financial report but rather a regulatory compliance and verification report related to a capital restructuring event. It does not contain financial statements or earnings data but focuses on the progress and regulatory compliance of a major asset restructuring and trading suspension. This fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes, including major asset restructurings and related trading suspensions.
2017-04-14 Chinese
关于重大资产重组停牌进展公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from a company regarding the progress of a major asset restructuring (重大资产重组停牌进展公告). It details the ongoing status of the transaction, including stock suspension, negotiations, due diligence, and expected timelines for disclosure and resumption of trading. The document does not contain financial statements or detailed financial analysis but serves as a progress update on a significant corporate event. It is not a full report like an Annual Report or Interim Report, nor is it a final merger filing. The document is an official announcement about the status of a major asset restructuring and stock suspension, fitting the category of Capital/Financing Update (CAP). The document length is short (2288 characters), and it is not merely announcing the publication of a report but providing substantive progress information. Therefore, the best classification is CAP with high confidence.
2017-04-12 Chinese
关于重大资产重组停牌进展公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement regarding the progress of a major asset restructuring and the related stock trading suspension. It details the timeline of suspension and progress updates, mentions ongoing due diligence and evaluation work, and states that the stock remains suspended to protect investors. The document is short (1093 characters) and serves as a progress update announcement rather than a full financial report or detailed filing. It does not contain financial statements or detailed analysis but is an update on a capital restructuring event. Therefore, it fits best under 'Capital/Financing Update' (CAP).
2017-04-05 Chinese
关于重大资产重组停牌进展公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from a company regarding the progress of a major asset restructuring and the related stock trading suspension. It details the timeline of suspension and progress announcements, references regulatory compliance, and states that further progress updates will be provided every five trading days. The document is short (1076 characters) and primarily serves as an update on the status of a capital restructuring event rather than providing detailed financial data or the restructuring report itself. This fits the category of a Capital/Financing Update (CAP) rather than a full report or announcement of a report publication. Therefore, the appropriate classification is CAP with high confidence.
2017-03-27 Chinese
关于重大资产重组停牌进展公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from a company regarding the progress of a major asset restructuring and the related stock trading suspension. It details the timeline of suspension and progress announcements, mentions ongoing due diligence and adjustments, and states that the stock remains suspended to protect investors. The document is short (1113 characters) and serves as a progress update on a capital restructuring event rather than a full financial report or detailed transaction filing. It does not contain financial statements or detailed merger documentation but is an ongoing status announcement related to a major asset reorganization. This fits best under Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as major asset restructurings and related trading suspensions.
2017-03-20 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.